NCT00258232View on ClinicalTrials.gov

Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

January 31, 2002

Primary Completion Date

March 31, 2007

Study Completion Date

August 31, 2007

Conditions
Colorectal Cancer
Interventions
DRUG

capecitabine

DRUG

celecoxib

DRUG

irinotecan hydrochloride

Trial Locations (3)

48109-0944

University of Michigan Comprehensive Cancer Center, Ann Arbor

48201-1379

Barbara Ann Karmanos Cancer Institute, Detroit

43210-1240

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT00258232 - Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter